peptide
Retatrutide
moderatePhase 2/3 Clinical TrialsInjection
Next-gen triple agonist from Eli Lilly hitting GLP-1, GIP, and glucagon receptors. Phase 2 showed 24.2% weight loss at 48 weeks — highest of any incretin therapy. At low doses, optimizes metabolism without major weight loss.
Key facts
- Classification
- Retatrutide (LY3437943) is a triple GIP/GLP-1/glucagon agonist.
- Primary benefits
- Fat Loss (10/10) · Brain & Cognition (5/10) · Longevity (5/10)
- Administration
- Injection
- Doses studied
- For health optimization: 2 mg per week (start at 1 mg for the first 4 weeks). For weight loss: gradually increase from 1 to 4 to 8 to 12 mg over months. Its long half-life (4-7 days) means you only inject once a week.
- Evidence strength
- Moderate — 21 peer-reviewed studies
- Stacks well with
- 5-Amino-1MQ, MOTS-c, SS-31, NAD+
- Legal status
- Phase 2/3 Clinical Trials · not prescribable in US · WADA prohibited
Quick stats
- Type
- Peptide
- Administration
- Injection
- Studies referenced
- 21
- Stacks with
- 5 peptides
- Regulatory
- Phase 2/3 Clinical Trials
Scientific overview
Retatrutide (LY3437943) is a triple GIP/GLP-1/glucagon agonist. The glucagon component adds thermogenic and lipolytic effects. Phase 2 showed 24.2% weight reduction at 48 weeks — the most potent weight loss in any obesity pharmacotherapy trial. Produces synergistic effects on energy expenditure and hepatic lipid metabolism.
Goal coverage · Retatrutide
🔥 Fat Loss10/10
🧠 Brain & Cognition5/10
⏳ Longevity5/10
🧊 Inflammation4/10
🫃 Gut Health3/10
Medical oversight requiredNot safe during pregnancy· 6 contraindications